For the first time, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody has shown that it can extend ...

The advancement of Pfizer’s antibody-drug conjugate portfolio has not spared the former Seagen site—and those who helped ...

Weeks after telegraphing a series of upgrades to its Mexico operations over the next five years, Bayer is rolling up its ...

In May, radiopharmaceutical drug developer Ratio Therapeutics unveiled plans to build a new research and manufacturing plant ...

Seeking to build out its pipeline-in-a-product Vyvgart, Argenx is returning to its roots with plans to pursue an expanded approval in the drug’s initial myasthenia gravis indication. | On Monday, ...

With a buyout of scPharmaceuticals worth up to $360 million, MannKind is looking to dive into the large and growing field of cardiometabolic treatments. | The company touts a large U.S. market ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

As Department of Health and Human Services (HHS) and FDA leadership continue to look for ways to boost transparency and ...

BeOne Medicines is monetizing its stake in Amgen’s first-in-class lung cancer drug Imdelltra for up to $950 million. | BeOne Medicines is monetizing its stake in Amgen’s first-in-class lung cancer ...

On a day when Bavarian Nordic reported strong first-half sales and adjusted its 2025 guidance positively, its CEO said that a ...

Despite boasting a new owner, the Indiana manufacturing plant Novo Nordisk picked up as part of its parent company's Catalent ...

The biopharma industry’s bid to increase drug spending in the U.K. has reached an impasse. | Talks between the U.K.